...sequencing initiative into new treatments that can delay progression for much longer periods of time. Treeway... ...potentially extend the life of ALS patients was being evaluated," said CEO Inez de Greef. Treeway's... ...and EU Orphan Drug designations. Treeway plans to start a Phase II/III trial in 2Q16. Treeway...
...sequencing initiative into new treatments that can delay progression for much longer periods of time. Treeway... ...potentially extend the life of ALS patients was being evaluated," said CEO Inez de Greef. Treeway's... ...and EU Orphan Drug designations. Treeway plans to start a Phase II/III trial in 2Q16. Treeway...